Shares of Esperion Therapeutics, Inc. (ESPR) were down in Tuesday's premarket session. The reason? The company just announced it's buying a smaller biotech firm called Corstasis Therapeutics. The price tag is $75 million in cash upfront, plus some potential future payments.

So, what is Esperion getting for its money? It's acquiring Corstasis, which developed a drug called Enbumyst. This isn't just any drug—it's the first diuretic for heart failure-related swelling that you take as a nasal spray, and it's already got the FDA's stamp of approval. The idea, according to the companies, is that this spray offers "meaningful innovation to millions of patients who continue to struggle with the daily burden of diuretic therapy." In other words, it might be easier for patients than taking more pills.

The Deal's Fine Print

Let's break down the numbers. Esperion is paying $75 million in cash right away to buy Corstasis. But that's not the whole story. There are also potential royalties and milestone payments tied to the deal that could add up to another $180 million down the road. So, the total value could eventually reach $255 million.

Where's the money coming from? Esperion says it will use its existing credit facilities and also monetize—that's finance-speak for selling the future income stream—its Japanese royalties. Funds managed by Athyrium Capital Management and HealthCare Royalty are involved in that royalty financing piece. As of the end of last September, Esperion had about $92.4 million in cash on hand. The companies expect the whole acquisition to be finalized in the second quarter of 2026.

Why Esperion Is Making This Move

This isn't just a random purchase. Esperion is a company focused on cardiovascular diseases. It already has a sales and commercial infrastructure built around that. The plan is to plug Enbumyst into that existing machine. Esperion's CEO, Sheldon Koenig, is pretty bullish on what this means.

"We expect that by integrating Enbumyst into our proven commercial platform, we will drive sustained double-digit growth, strengthen our leadership in cardiovascular care, and create durable value for all of our stakeholders – from patients and providers to employees and shareholders," Koenig said.

The company sees a big opportunity here. It's targeting a U.S. market that it believes is worth more than $4 billion. The goal is for this acquisition to boost the company's overall revenue growth into the double digits.

What the Charts Are Saying

Let's talk about the stock's recent performance, because it hasn't been great. A quick technical analysis shows the stock is currently trading about 5.5% below its 20-day simple moving average and 12.3% below its 100-day average. That generally points to a bearish trend over the short to medium term. Over the past year, the shares have fallen significantly and are sitting much closer to their 52-week lows than their highs.

Some other indicators paint a mixed picture. The Relative Strength Index (RSI) is at 44.45, which is considered neutral—not overbought or oversold. However, the MACD indicator is at 0.15, which is below its signal line of 0.22. That's typically seen as a bearish signal. So, you have neutral momentum from one indicator and bearish pressure from another. Traders might be watching key resistance at the $4.00 level and key support at $2.50.

The Upcoming Earnings and What Analysts Think

Mark your calendars: Esperion is scheduled to report its next earnings on March 10, 2026. The expectations are for a notable turnaround. Analysts are forecasting earnings per share of 26 cents. That's up from a loss of 11 cents in the prior period. Revenue is also expected to jump to $163.31 million, up from $69.11 million.

Despite the stock's weak price action, the analyst community is largely positive on Esperion. The stock carries a consensus Buy rating with an average price target of $6.31. That's well above where it's trading now. Some recent analyst actions include:

• Piper Sandler: Initiated coverage with an Overweight rating and a $9.00 price target on November 25, 2025.
• HC Wainwright & Co.: Maintained a Buy rating with a $16.00 price target on September 19, 2025.

So, you have a situation where the stock price is struggling, but Wall Street analysts see significant upside. That's a classic disconnect that investors watch closely.

As of the premarket session on Tuesday, Esperion shares were down 5.40%, trading at $3.09.